Online inquiry

IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8197MR)

This product GTTS-WQ8197MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLC39A6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001099406.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 25800
UniProt ID Q13433
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8197MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15796MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ9105MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ15388MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ8704MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ6301MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ12212MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ5804MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ6926MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW